Literature DB >> 21179310

Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data.

Sameh K Morcos1, John Haylor.   

Abstract

Since the association between nephrogenic systemic fibrosis (NSF) and gadolinium contrast agents (Gd-CAs) was suggested in 2006, several experimental studies have been published to elucidate the role of these agents in the pathogenesis of NSF. Low stability Gd-CAs have a stimulant effect on human skin and fibroblasts in culture and modulate the production of collagen by these cells. Low stability agents have also induced NSF-like skin changes in a rat model with normal renal function after multiple repeat administrations. The role of the 5/6 subtotal nephrectomy rat model in investigating NSF remains under evaluation.

Entities:  

Keywords:  Experimental models; Gadolinium-based contrast agents; Nephrogenic systemic fibrosis; Pathophysiology

Year:  2010        PMID: 21179310      PMCID: PMC3006481          DOI: 10.4329/wjr.v2.i11.427

Source DB:  PubMed          Journal:  World J Radiol        ISSN: 1949-8470


  26 in total

1.  The relationship between thermodynamics and the toxicity of gadolinium complexes.

Authors:  W P Cacheris; S C Quay; S M Rocklage
Journal:  Magn Reson Imaging       Date:  1990       Impact factor: 2.546

2.  Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents.

Authors:  Sophie Laurent; Luce Vander Elst; Robert N Muller
Journal:  Contrast Media Mol Imaging       Date:  2006 May-Jun       Impact factor: 3.161

3.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

4.  "Stability" of gadolinium chelates.

Authors:  M F Tweedle
Journal:  Br J Radiol       Date:  2007-07       Impact factor: 3.039

5.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

6.  Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts.

Authors:  James Varani; Marissa DaSilva; Roscoe L Warner; Monica O'Brien Deming; Adam G Barron; Kent J Johnson; Richard D Swartz
Journal:  Invest Radiol       Date:  2009-02       Impact factor: 6.016

7.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.

Authors:  Marc Port; Jean-Marc Idée; Christelle Medina; Caroline Robic; Monique Sabatou; Claire Corot
Journal:  Biometals       Date:  2008-03-15       Impact factor: 2.949

8.  Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy.

Authors:  Gregory W White; Wendell A Gibby; Michael F Tweedle
Journal:  Invest Radiol       Date:  2006-03       Impact factor: 6.016

9.  Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.

Authors:  M Edward; J A Quinn; S Mukherjee; M-B V Jensen; A G Jardine; P B Mark; A D Burden
Journal:  J Pathol       Date:  2008-04       Impact factor: 7.996

10.  Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents.

Authors:  Hubertus Pietsch; Philipp Lengsfeld; Gregor Jost; Thomas Frenzel; Joachim Hütter; Martin A Sieber
Journal:  Eur Radiol       Date:  2009-01-24       Impact factor: 5.315

View more
  5 in total

1.  Scleroderma Mimickers.

Authors:  Nadia D Morgan; Laura K Hummers
Journal:  Curr Treatm Opt Rheumatol       Date:  2016-02-05

2.  Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report.

Authors:  Beatrice Nardone; Elise Saddleton; Anne E Laumann; Beatrice J Edwards; Dennis W Raisch; June M McKoy; Steven M Belknap; Christian Bull; Anand Haryani; Shawn E Cowper; Ali K Abu-Alfa; Frank H Miller; Victoria Godinez-Puig; Vikas R Dharnidharka; Dennis P West
Journal:  Pediatr Radiol       Date:  2013-09-21

Review 3.  Scleroderma mimics.

Authors:  Jennifer Nashel; Virginia Steen
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

4.  Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.

Authors:  Emmanuil Smorodinsky; David S Ansdell; Zeke W Foster; Sameer M Mazhar; Irene Cruite; Tanya Wolfson; Sebastian B Sugay; Gabriella Iussich; Masoud Shiehmorteza; Yuko Kono; Alexander Kuo; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2014-05-09       Impact factor: 4.813

Review 5.  How the Chemical Properties of GBCAs Influence Their Safety Profiles In Vivo.

Authors:  Quyen N Do; Robert E Lenkinski; Gyula Tircso; Zoltan Kovacs
Journal:  Molecules       Date:  2021-12-23       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.